<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258180</url>
  </required_header>
  <id_info>
    <org_study_id>03-07-08-04</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0326</secondary_id>
    <secondary_id>J0326</secondary_id>
    <secondary_id>CDR0000441133</secondary_id>
    <nct_id>NCT00258180</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy</brief_title>
  <official_title>High-Dose Cyclophosphamide for the Treatment of Severe Autoimmune Enteropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy .

      PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young
      patients with severe autoimmune enteropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the rate of treatment-free remission in young patients with severe autoimmune
           enteropathy treated with high-dose cyclophosphamide.

      Secondary

        -  Determine the toxic effects of this drug in these patients.

      OUTLINE: Patients receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive
      filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3
      days or until blood counts recover.

      After completion of study treatment, patients are followed periodically for up to 1½ years.

      PROJECTED ACCRUAL: A total of 7-11 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2005</start_date>
  <completion_date type="Actual">February 24, 2009</completion_date>
  <primary_completion_date type="Actual">February 24, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-free Remission at 1 Year After Study Completion</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants off therapy 1 year after study completion without relapse.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Diarrhea</condition>
  <condition>Gastrointestinal Complications</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>severe autoimmune enteropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover</description>
    <arm_group_label>severe autoimmune enteropathy</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Administered IV over 1 hour on days 1-4</description>
    <arm_group_label>severe autoimmune enteropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of severe autoimmune enteropathy

               -  Condition is resistant to conventional therapy

          -  Histologic evidence of severe villous atrophy with intense lymphocytic infiltrate of
             the lamina propria by small intestinal biopsy within the past 3 months

          -  Disease failed to respond after ≥ 2 months of corticosteroid therapy at a dose of ≥
             0.5 mg/kg/day or ≥ 40 mg/day for patients &gt; 20 kg AND 1 of the following therapies:

               -  Cyclosporine resulting in ≥ 1 whole blood level of &gt; 200 ng/mL

               -  Tacrolimus resulting in ≥ 1 whole blood level of 5 ng/mL

          -  At least 50% estimated caloric needs provided by parenteral nutrition

          -  History of intractable diarrhea, defined as frequent watery stools for &gt; 3 months that
             does not respond to dietary restriction

          -  No celiac disease, defined by a history of positive antiendomysial antibody or tissue
             transglutaminase antibody

          -  No primary immunodeficiency or x-linked autoimmunity-allergy dysregulation

        PATIENT CHARACTERISTICS:

        Performance status

          -  Lansky 60-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Cardiovascular

          -  Ejection fraction ≥ 40% OR shortening fraction ≥ 20%

        Pulmonary

          -  FVC or FEV_1 ≥ 50% of predicted (for patients &gt; 8 years of age)

          -  No clinically abnormal pulmonary function or abnormal pulse oximetry (for patients ≤ 8
             years of age)

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 9 months
             after completion of study treatment

          -  No known chromosomal abnormality

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No immunizations for at least 6 months after completion of study treatment

        Endocrine therapy

          -  See Disease Characteristics

          -  At least 5 days since prior corticosteroids

          -  No concurrent dexamethasone as an anti-emetic

        Other

          -  At least 5 days since other prior immunosuppressive medications (e.g., tacrolimus or
             cyclosporine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Loeb, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Oliva-Hemker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <results_first_submitted>November 28, 2016</results_first_submitted>
  <results_first_submitted_qc>March 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>gastrointestinal complications</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 subject was not assigned intervention due to PI decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Severe Autoimmune Enteropathy</title>
          <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Severe Autoimmune Enteropathy</title>
          <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-free Remission at 1 Year After Study Completion</title>
        <description>Number of participants off therapy 1 year after study completion without relapse.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Autoimmune Enteropathy</title>
            <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-free Remission at 1 Year After Study Completion</title>
          <description>Number of participants off therapy 1 year after study completion without relapse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month</title>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Severe Autoimmune Enteropathy</title>
            <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
filgrastim: Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
cyclophosphamide: Administered IV over 1 hour on days 1-4</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Intervention-related Adverse Events, as Defined by CTCAE at 1 Month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 1 year post-intervention</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Severe Autoimmune Enteropathy</title>
          <description>Young patients with severe autoimmune enteropathy receive cyclophosphamide IV over 1 hour on days 1-4. Patients then receive filgrastim (G-CSF) IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria Oliva-Hemker MD</name_or_title>
      <organization>Johns Hopkins School of Medicine</organization>
      <phone>410-955-8769</phone>
      <email>moliva@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

